Chief Executive Officer Dr Howie McKibbon will present to institutional investors at today’s Canaccord Drug and Device Healthcare Conference in Noosa. For the balance of the week, Canaccord Genuity will host a Botanix investor roadshow.
The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q1 FY2026 have been released. Quarter over quarter, total prescriptions for Sofdra® (sofpironium) increased 50% to 20,418 as operating cash outflow decreased 54% to $13.1 million. Net revenue was $7.1 million.
Join our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on Monday 20 October at 11.00 am AEDT / 8.00 am AWST for an important update.
Participants must pre-register: Click here
